CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy (Q39284720)

10 September 2017

CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy (English)

1 reference

10 September 2017

1 reference

1 reference

1 reference

Elisabeth G E De Vries

1 reference

10 September 2017

Thijs H Oude Munnink

1 reference

10 September 2017

Hetty Timmer-Bosscha

1 reference

10 September 2017

Wouter B Nagengast

1 reference

10 September 2017

Annemiek M E Walenkamp

object named as

Annemiek M E Walenkamp

1 reference

10 September 2017

Igle J de Jong

1 reference

10 September 2017

Hildo J K Ananias

1 reference

10 September 2017

Urszula M Domanska

1 reference

10 September 2017

Roeliene C Kruizinga

1 reference

10 September 2017

Nathalie M Kliphuis

1 reference

10 September 2017

Gerwin Huls

1 reference

10 September 2017

1 August 2012

1 reference

10 September 2017

1 reference

10 September 2017

1 reference

10 September 2017

1 reference

10 September 2017

709-718

1 reference

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

Leukemia Stem Cells and Microenvironment: Biology and Therapeutic Targeting

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

DNA damage-mediated induction of a chemoresistant niche

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

Estimates of cancer incidence and mortality in Europe in 2008.

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

Cancer-associated stromal fibroblasts promote pancreatic tumor progression

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

CXCR4 regulates growth of both primary and metastatic breast cancer

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors.

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

Altered TGF-β signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis.

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

Resistance mechanisms in three human small cell lung cancer cell lines established from one patient during clinical follow-up

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region.

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

CXCR4 Expression Predicts Patient Outcome and Recurrence Patterns after Hepatic Resection for Colorectal Liver Metastases

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431178

Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone

2 December 2018

1 reference

12 December 2020

Expression of CXCR4 Predicts Poor Prognosis in Patients with Malignant Melanoma

1 reference

12 December 2020

Chemokines and cancer

1 reference

12 December 2020

Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer

1 reference

12 December 2020

CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model

1 reference

12 December 2020

Identifiers

DOI

10.1593/NEO.12324

1 reference

release_34uizgroqjggzeshd6iygt4nyy

10 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/34uizgroqjggzeshd6iygt4nyy

24 November 2022

mapped directly with Wikidata item

1 reference

10 September 2017

PubMed publication ID

22952424

1 reference